<SEC-DOCUMENT>0001558370-23-009504.txt : 20230512
<SEC-HEADER>0001558370-23-009504.hdr.sgml : 20230512
<ACCEPTANCE-DATETIME>20230512073620
ACCESSION NUMBER:		0001558370-23-009504
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230512
DATE AS OF CHANGE:		20230512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		23913177

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adap-20230512x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/11/2023 11:27:34 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 25876656-d078-42e0-a175-4cb5e03a60ad -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adap="http://www.adaptimmune.com/20230512" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityCentralIndexKey" id="Tc_BHNC9rZbGkCG4ie0X24FTQ_2_1">0001621227</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:AmendmentFlag" id="Tc_XVVBD70Tn0GGcP8ZjSTI3A_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityTaxIdentificationNumber" id="Hidden_BaeV3aqDwUOBC-fJo8d2Jw">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adap-20230512.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f14fe020_5aa2_4e89_b571_5de386906f2b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES </b><b style="font-size:18pt;font-weight:bold;"><br /></b><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:DocumentType" id="Narr_8bZbWT-DIEyDS7X0YLDGug"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported):<b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_nO0Pu-7nbESSRa8gTJSl7w"><b style="font-weight:bold;">May 12, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityRegistrantName" id="Narr_KC_A0m0xrkiU-PHQfKR_gA"><b style="font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a955ef0e_e52b_4858_9ce4_6782eccbb535"></a><a id="Tc_iiXQG8KXrkqT8D7K9X8voA_2_0"></a><a id="Tc_TfizrS1yokm3D9y4l0MiyA_2_2"></a><a id="Tc_V0Alw1X8TUetUMLQOd44Jw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_-ssh2WX-EUGd9W1GK2Ayfg_1_0"><b style="font-weight:bold;">England and Wales</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityFileNumber" id="Tc_WuG8UCvZVk6dG2cs1TeI5g_1_2"><b style="font-weight:bold;">1-37368</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_BaeV3aqDwUOBC-fJo8d2Jw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Not Applicable</b></span></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityAddressAddressLine1" id="Narr_igg612w8WE2Yl8TKo3Pn7A"><b style="font-weight:bold;">60 Jubilee Avenue</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityAddressAddressLine2" id="Narr_tAFaxb8yXEi676wIukVY0A"><b style="font-weight:bold;">Milton Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityAddressCityOrTown" id="Narr_Pvs_6DcuykyJuaSPoTvpqA"><b style="font-weight:bold;">Abingdon, Oxfordshire</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:EntityAddressPostalZipCode" id="Narr_QJ_9qt237kWRPA9u3vcQiA"><b style="font-weight:bold;">OX14 4RX</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_aA7EA3psL0SXmUuNaqX2pg"><b style="font-weight:bold;">United Kingdom</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:CityAreaCode" id="Narr_Ibl_bXNPLku-JIH7lyLfTQ"><b style="font-weight:bold;">44</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:LocalPhoneNumber" id="Narr_4AvE-d2AREqCtRtgOROALA"><b style="font-weight:bold;">1235 430000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_nWPOTxVl9US8UK15J13Xgg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_bSBIpg7iaUa0VgED5cByqg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_YBcU_uS3IEGReLwxdv9qAA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_pEHNQnSX00KpdSbXKwHa_g"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_602dac61_edc2_4936_8590_9ecf753fb00c"></a><a id="Tc_ZHkxR7mwp0qvBYO9Px-TGQ_0_0"></a><a id="Tc_XNRs746ghEe9I6KbhL8X6w_0_2"></a><a id="Tc_vqm2vv4DUkS6Lp45Xf1PQw_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">registered</b></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:Security12bTitle" id="Tc_0z11C1qmCEOIfbqE7ljezQ_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" name="dei:TradingSymbol" id="Tc_kj5UasHEsk6YPlIxhTGWJQ_1_2">ADAP</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_YiQYCxVxh0KEyVpB8-QZXA_1_4">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_WXxOJE5WLEuDKtl8z00KMA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_daa0ae8e_f1ac_4392_bbe7_f0a6bca813f9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2.02</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Results of Operations and Financial Conditions.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2023, Adaptimmune Therapeutics plc (the &#8220;Company&#8221;) announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information in Item 2.02 of this Current Report on Form 8-K, including the Exhibit 99.1 attached hereto, shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &quot;Exchange Act&quot;), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing. </p><a id="_38d4838a_2945_467c_b7c9_c725a50894d9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#160; Exhibits.</p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="adap-20230512xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated May 12, 2023.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAPTIMMUNE THERAPEUTICS PLC</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 12, 2023</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adap-20230512xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/11/2023 11:27:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:27.8pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><img src="adap-20230512xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:49.95pt;width:226.5pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Reports First Quarter Financial Results and Business Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">Completed submission of the clinical module (Part 2) of the afami-cel BLA; <br>afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs; Adaptimmune will receive ~$37 million in upfront and milestone payments</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">Announced strategic combination with TCR<sup style="font-size:8.25pt;vertical-align:top;">2</sup> to create a preeminent cell therapy company for solid tumors; following closing of the transaction in Q2 2023, cash runway extended into early 2026</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="background:#ffffff;">Webcast to be held today, May 12, 2023, at 8:00 a.m. EDT (1:00 p.m. BST)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">PHILADELPHIA, PA. and OXFORD, UK, May 12, 2023 &#8211; Adaptimmune Therapeutics plc<font style="background:#ffffff;">&#160;(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the first quarter ended </font>March 31, 2023 and provided a business update<font style="background:#ffffff;">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Adrian Rawcliffe, Adaptimmune&#8217;s Chief Executive Officer:</b> &#8220;We have entered 2023 at pace with the announcement of the strategic combination with TCR<sup style="font-size:8.25pt;vertical-align:top;">2</sup>, the finalization of the return of lete-cel from GSK and continued excellent progress on the rolling BLA submission to make afami-cel a transformative therapy for people with synovial sarcoma. In addition, we are deploying ADP-A2M4CD8 in ovarian cancer with the SURPASS-3 clinical trial. Following the strategic combination with TCR<sup style="font-size:8.25pt;vertical-align:top;">2</sup>, the combined company will have the most robust and advanced pipeline in the solid tumor cell therapy field and will position us as a preeminent integrated cell therapy company with a cash runway into early 2026.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:14pt;font-style:italic;font-weight:bold;background:#ffffff;">Afami-cel - Adaptimmune&#8217;s first potential commercial product for the treatment of synovial sarcoma</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">BLA update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="background:#ffffff;">In Q1 2023, Adaptimmune completed submission of </font>the clinical module (Part 2) of the afami-cel BLA<font style="background:#ffffff;">, which is targeted for completion in mid-2023. This BLA is supported by data from Cohort 1 of the pivotal trial SPEARHEAD-1, which met its primary endpoint for efficacy. The Company has Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for afami-cel for the treatment of synovial sarcoma. Cohort 2 of the SPEARHEAD-1 trial has completed recruitment. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Data presentations </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">ASGCT:</b> Translational analyses for afami-cel will be showcased on May 18<sup style="font-size:8.25pt;vertical-align:top;">th</sup> at 4:00 p.m. PST during the Cell Therapy Product Engineering and Development oral session in Room 502AB at the upcoming American Society of Cell and Gene Therapy (ASGCT) Annual Meeting in a presentation entitled &#8220;Mechanistic Characterization of Afamitresgene Autoleucel.&#8221; These analyses seek to correlate in-vitro T-cell effector functions with patient response<font style="color:#203864;">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">ASCO:</b><font style="background:#ffffff;"> Data from SPEARHEAD-1 will be presented on June 3</font><sup style="font-size:8.25pt;vertical-align:top;background:#ffffff;">rd </sup><font style="background:#ffffff;">at </font>1:15 p.m. CDT during the Sarcoma Track Poster Session in Hall A <font style="background:#ffffff;">at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in a presentation entitled: &#8220;The SPEARHEAD-1 trial of afamitresgene autoleucel (&quot;afami-cel&quot;): Analysis of overall survival in advanced synovial sarcoma.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">AACR:</b><font style="background:#ffffff;"> Translational data from patients with sarcoma who received afami-cel were presented at the American Association for Cancer Research (AACR) annual meeting in April. Data demonstrated engagement of the broader immune system after a single dose of afami-cel correlating with durable antitumor activity (poster can be accessed </font><u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">here</u><font style="background:#ffffff;">). These data further support the use of afami-cel for the treatment of synovial sarcoma.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:14pt;font-style:italic;font-weight:bold;background:#ffffff;">ADP-A2M4CD8 &#8211; Adaptimmune&#8217;s next-generation product with responses in multiple solid tumor indications</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Initiating the Phase 2 SURPASS-3 trial in combination with nivolumab for platinum resistant ovarian cancer. This trial has the potential to become registrational. ADP-A2M4CD8 has been granted FDA RMAT designation for treatment of patients with platinum resistant ovarian cancer.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Initiating additional cohorts in the Phase 1 SURPASS trial in combination with pembrolizumab to treat patients in the first-line treatment setting for head &amp; neck cancer and second-line setting for urothelial cancer.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:14pt;font-style:italic;font-weight:bold;background:#ffffff;">Additional pipeline updates</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs back to Adaptimmune. </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Adaptimmune will receive ~$37 million from GSK in relation to the transition of the ongoing NY-ESO clinical trials</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Adaptimmune will continue to focus on its MAGE-A4 franchise while determining the optimal development path for complementary PRAME and NY-ESO programs</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Partnered programs with Genentech continue with the allogeneic pipeline </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:14pt;font-style:italic;font-weight:bold;background:#ffffff;">Strategic combination with TCR</font><sup style="font-size:10.5pt;font-style:italic;font-weight:bold;vertical-align:top;background:#ffffff;">2</sup></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Adaptimmune announced a strategic combination with TCR&#178; Therapeutics Inc.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">As a result, and following the closing of the transaction, it is anticipated that the combined company&#8217;s cash runway will extend into 2026.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Adaptimmune General Meeting will be held on May 30, 2023 and, subject to receipt of approvals of Adaptimmune shareholders and TCR&#178; stockholders and satisfaction or waiver of other closing conditions, the transaction is expected to close in Q2 2023, following which Adaptimmune shareholders will own approximately 75% of the combined company and TCR</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">2</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> stockholders will own approximately 25% of the combined company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Further information about the combined pipeline, catalysts and changes to the Board of Directors was provided in the March Press Release. </font><u style="color:#0000ff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;"> </u></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Results for the first quarter ended March 31, 2023</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Cash / liquidity position:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> As of March 31, 2023, Adaptimmune had cash and cash equivalents of $119.9 million and Total Liquidity</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-2">1</a></sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> of $165.6 million, compared to $108.0 million and $204.6 million, respectively, as of December 31, 2022.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Revenue</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: Revenue for the first quarter ended March 31, 2023 was $47.6 million, compared to $3.6 million for the same period in 2022. Revenue has increased primarily due to the termination of the Astellas collaboration, resulting in a release of the remaining deferred income for the collaboration being released as revenue in March 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Research and development (R&amp;D) expenses:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> R&amp;D expenses for the first quarter ended March 31, 2023 were $25.5 million, compared to $36.8 million for the same period in 2022. R&amp;D expenses decreased due to a decrease in the average number of employees engaged in research and development, decreases in subcontracted expenditures, a decrease in share-based compensation expenses and a decrease in offsetting reimbursements receivable for research and development tax and expenditure credits. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">General and administrative (G&amp;A) expenses:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> G&amp;A expenses for the first quarter ended March 31, 2023 were $20.4 million, compared to $16.8 million for the same period in 2022 due to restructuring charges recognised in the quarter and an increase in other corporate costs due to an increase in accounting, legal and professional fees incurred in relation to the TCR2 Therapeutics Inc merger agreement, offset by a decrease in share-based compensation expenses. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Net profit/(loss):</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Net profit attributable to holders of the Company&#8217;s ordinary shares for the first quarter ended March 31, 2023 was $1.0 million ($0.00 profit per ordinary share), compared to a net loss of $50.3 million ($(0.05) loss per ordinary share), for the same period in 2022.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Guidance</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech and payments under the Termination and Transfer Agreement with GSK, will fund the Company&#8217;s current operations into early 2025, as further detailed in the Company&#8217;s Quarterly Report on Form 10-Q for the first quarter ended March 31, 2023<font style="white-space:pre-wrap;">, to be filed with the Securities and Exchange Commission following this earnings release.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">On March 6, 2023 the Company announced entry into a merger agreement under which the Company will combine with TCR&#178; Therapeutics Inc in an all-stock transaction. Following the closing of the transaction, we currently estimate that the cash runway of the combined company will extend into early 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Webcast Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="background:#ffffff;">The Company will host a live webcast to provide additional details </font><font style="background:#ffffff;">at 8:00 a.m. EDT (1:00 p.m. BST) today, May 12, 2023. A live webcast of the conference call and replay can be accessed at </font>&#160;<u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">https://www.gowebcasting.com/12528</u><font style="background:#ffffff;">. Call in information is as follows: (800)-319-4610 (US or Canada) or +1 (416)-915-3239 (International and additional options available&#160;</font><u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">HERE</u><font style="background:#ffffff;">). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">About Adaptimmune</b></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup> Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="background:#ffffff;">Adaptimmune&#160;is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company&#8217;s unique SPEAR&#160;(Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger, dated March 5, 2023, as amended on April 5, 2023, by and among Adaptimmune Therapeutics plc (&#8220;Parent&#8221;), CM Merger Sub, Inc. (&#8220;Merger Sub&#8221;), and TCR&#178; Therapeutics Inc. &#160;(the &#8220;Company&#8221;). This communication includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), about the proposed transaction between &#160;Parent and the Company and the operations of the combined company that involve risks and uncertainties relating to future events and the future performance of Parent and the Company. Actual events or results may differ materially from these forward-looking statements. Words such as &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;future,&#8221; &#8220;opportunity&#8221; &#8220;will likely result,&#8221; &#8220;target,&#8221; variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, satisfaction of closing conditions to the proposed transaction, prospective performance and opportunities with respect to Parent or the Company, post-closing operations and the outlook for the companies&#8217; businesses; Parent&#8217;s, the Company&#8217;s or the combined company&#8217;s targets, plans, objectives or goals for future operations, including those related to Parent&#8217;s and the Company&#8217;s product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation thereto; projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; future economic performance, future actions and outcome of contingencies such as legal proceedings; and the assumptions underlying or relating to such statements. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt;">These statements are based on Parent&#8217;s and the Company&#8217;s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Parent&#8217;s and/or the Company&#8217;s ability to obtain the approval of Parent&#8217;s shareholders or the Company&#8217;s stockholders required to consummate the proposed transaction&#894; the possibility that competing offers will be made by third parties&#894; the occurrence of events that may give rise to a right of one or both of Parent and the Company to terminate the merger agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected by Parent and the Company, or at all; the risk that Parent and Company may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt;">effects of the proposed transaction on relationships with Parent&#8217;s or the Company&#8217;s employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price of Parent&#8217;s American Depositary Shares or the Company&#8217;s common stock and/or Parent&#8217;s or the Company&#8217;s operating or financial results; uncertainties as to the long-term value of Parent&#8217;s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Parent&#8217;s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the proposed transaction; unknown liabilities related to Parent or the Company; the nature, cost and outcome of any litigation and other legal proceedings involving Parent, the Company or their respective directors, including any legal proceedings related to the proposed transaction; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of Parent&#8217;s or the Company&#8217;s programs or product candidates; risks related to any loss of Parent&#8217;s or the Company&#8217;s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for Parent or the Company&#8217;s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by Parent, the Company and/or their respective collaborators or licensees; the extent to which the results from the research and development programs conducted by Parent, the Company, and/or their respective collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Parent or the Company&#8217;s product candidates, and the impact of studies (whether conducted by Parent, the Company or others and whether mandated or voluntary) on any of the foregoing; unexpected breaches or terminations with respect to Parent&#8217;s or the Company&#8217;s material contracts or arrangements; risks related to competition for Parent&#8217;s or the Company&#8217;s product candidates; Parent&#8217;s or the Company&#8217;s ability to successfully &#160;develop or commercialize Parent&#8217;s or the Company&#8217;s product candidates; Parent&#8217;s, the Company&#8217;s, and their collaborators&#8217; abilities to continue to conduct current and future developmental, preclinical and clinical programs; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of Parent&#8217;s or the Company&#8217;s product candidates; unexpected increase in costs and expenses with respect to the potential transaction or Parent&#8217;s or the Company&#8217;s business or operations; and risks and uncertainties related to epidemics, pandemics or other public health crises and their impact on Parent&#8217;s and the Company&#8217;s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials, strategy, goals and anticipated milestones. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. A more complete description of these and other material risks can be found in Parent&#8217;s and the Company&#8217;s respective filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including each of their Annual Reports on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">Form 10-Q and other documents that may be filed from time to time with the SEC, as well as, the Registration Statement on Form S-4 which includes the joint proxy statement of Parent and the Company that also constitutes the prospectus of Parent, which joint proxy statement/prospectus has been mailed or otherwise disseminated to Parent&#8217;s shareholders and the Company&#8217;s stockholders on or about April 24, 2023. Parent and the Company also plan to file other relevant documents with the SEC regarding the proposed transaction. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of Parent&#8217;s and the Company&#8217;s management, and the reader is cautioned not to rely on any forward-looking statements made by Parent or the Company. Unless required by law, neither Parent nor the Company is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">No Offer or Solicitation</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="background:#ffffff;">This communication is not intended to and shall not constitute an offer to subscribe for, buy or sell or the solicitation of an offer to subscribe for, buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of, or offer to sell or buy, securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is for informational purposes only. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Additional Information and Where to Find It</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="background:#ffffff;">In connection with the proposed transaction, Parent and the Company filed with the SEC a Registration Statement on Form S-4. The Registration Statement on Form S-4 includes a document that serves as a prospectus of Parent and a joint proxy statement of Parent and the Company, and each party may also file other documents regarding the proposed transaction with the SEC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><font style="background:#ffffff;">Parent and the Company mailed or otherwise provided to its respective shareholders and stockholders the joint proxy statement/prospectus and other relevant documents in connection with the proposed transaction on or about April 24, 2023. Before making a voting decision, Parent shareholders and the Company stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by each of Parent and the Company with the SEC in connection with the proposed transaction or incorporated by reference therein carefully and in their entirety because they will contain important information about Parent, the Company and the proposed transaction. You may obtain a copy of these materials (when they are available) and other documents filed by Parent and the Company with the SEC for free at the SEC&#8217;s website at www.sec.gov. Copies of the documents filed with the SEC by the Company are available free of charge on the Company&#8217;s website at https://investors.tcr2.com/ or by contacting the Company&#8217;s Investor Relations Department at https://investors.tcr2.com/contact-ir. Copies of the documents filed with the SEC by Parent are available free of charge on Parent&#8217;s website at https://www.adaptimmune.com/investors-and-media/sec-filings or by contacting Parent&#8217;s Investor Relations Department at IR@adaptimmune.com.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Participants in the Solicitation</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><font style="background:#ffffff;">Parent, the Company and certain of their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Parent, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Parent&#8217;s proxy statement for its 2023 Annual General Meeting, which was filed with the SEC on April 13, 2023, the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on &#160;March 6, 2023, </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="background:#ffffff;">subsequent Quarterly Reports on Form 10-Q and other documents that may be filed from time to time with the SEC. Information about the directors and executive officers of the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company&#8217;s proxy statement for its 2022 Annual Meeting of Stockholders, which was filed with the SEC on September 1, 2022, the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 23, 2023, subsequent Quarterly Reports on Form 10-Q and other documents that may be filed from time to time with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the joint proxy statement/prospectus included in the Registration Statement on Form S-4 and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Security holders, potential investors and other readers should read the joint proxy statement/prospectus included in the Registration Statement on Form S-4 carefully before making any voting or investment decision. You may obtain free copies of these documents from Parent or the Company using the sources indicated above.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total Liquidity (a non-GAAP financial measure)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 119,866</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 108,033</font></p></td></tr><tr><td style="vertical-align:bottom;width:66.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Marketable securities - available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,688</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 96,572</font></p></td></tr><tr><td style="vertical-align:bottom;width:66.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liquidity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 165,554</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 204,605</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4pt;"><td style="vertical-align:bottom;width:66.75%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Condensed Consolidated Statement of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(unaudited, in thousands, except per share data)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 47,601</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,575</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (25,548)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (36,752)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (20,397)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (16,804)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (45,945)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (53,556)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating profit/(loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,656</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (49,981)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 676</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 338</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Other (expense) income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (671)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Profit/(loss) before income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,661</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (49,631)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (625)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (634)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net profit/(loss) attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,036</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (50,265)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net profit/(loss) per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 0.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.05)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 0.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.05)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average shares outstanding:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 991,330,402</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 940,029,247</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,000,276,615</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 940,029,247</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(unaudited, in thousands, except share data)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 119,866</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 108,033</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Marketable securities - available-for-sale debt securities</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,688</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 96,572</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Accounts receivable, net of allowance for expected credit losses of $0 and $0</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,715</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 7,435</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Other current assets and prepaid expenses</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 46,479</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,330</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 213,748</b></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 255,370</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,578</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,569</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets, net of accumulated amortization of $10,296 and $9,470</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 17,947</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 18,019</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Property, plant&#160;and equipment, net of accumulated depreciation of $38,534 and $38,588</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 54,365</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 53,516</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Intangible assets, net of accumulated amortization of $4,904 and $4,676</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 443</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 442</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 288,081</b></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 328,916</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,187</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,753</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,842</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,728</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 33,210</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 31,215</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Restructuring provision</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 88</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,285</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Deferred revenue, current</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 22,304</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 23,520</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 63,631</b></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 64,501</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 19,991</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 20,349</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Deferred revenue, non-current</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 119,251</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 160,892</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;">Other liabilities, non-current</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,332</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,296</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 204,205</b></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 247,038</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Common stock - Ordinary shares par value &#163;0.001, 1,282,773,750 authorized and 993,699,960 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890&#160;issued&#160;and outstanding)</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,407</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,399</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 992,520</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 990,656</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,785)</font></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (875)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (908,266)</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (909,302)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total stockholders&#39; equity</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 83,876</b></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 81,878</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 288,081</b></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 328,916</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Cash Flow Statement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">(unaudited, in thousands)</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Net profit/(loss)</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,036</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (50,265)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Adjustments to reconcile net profit/(loss) to net cash used in operating activities:</i></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,659</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,386</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 186</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 209</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,676</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,586</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Unrealized foreign exchange losses/(gains)</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 563</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (244)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Amortization on available-for-sale debt securities</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 112</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 999</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 134</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 220</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Changes in operating assets and liabilities:</i></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Decrease/(increase) in receivables and other operating assets</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,683</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,759)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Increase in payables and other current liabilities</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 21</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 964</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Decrease in deferred revenue</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (46,353)</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,497)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (37,283)</b></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,401)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Acquisition of property, plant&#160;and equipment</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,349)</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (7,114)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Acquisition of intangible assets</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (173)</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Maturity or redemption of marketable securities</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 50,863</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 44,536</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Investment in marketable securities</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (42,197)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash provided by/(used in) investing activities</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 48,341</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (4,775)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock from offerings, net of commissions and issuance costs</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 188</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 35</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 196</b></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 35</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;">Effect of currency exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 588</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,270)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Net increase/(decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 11,842</font></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (60,411)</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at start of period</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 109,602</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 151,666</font></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash at end of period</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 121,444</b></p></td><td style="vertical-align:bottom;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 91,255</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Contact</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Investor Relations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Juli P. Miller, Ph.D. &#8212; VP, Corporate Affairs and Investor Relations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">T: +1 215 825 9310</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">M: +1 215 460 8920</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><u style="color:#0000ff;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">Juli.Miller@adaptimmune.com</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#0000ff;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Media Relations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Dana Lynch, Senior Director of Corporate Communications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">M: +1 267 990 1217</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><u style="color:#0000ff;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">Dana.Lynch@adaptimmune.com</u></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:6.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>adap-20230512xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adap-20230512xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !) 4L# 2(  A$! Q$!_\0
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MJ>@T5^9/ASXY_'GX_?%R"_\ !UW=17-L28]/L\+IUI"W!\X-\K ^KY8G[O(
M'Z.^';Z_33=/M?$$NFQ^(G@WW$&GRL8F8<,T8<!RO3J.,XK"C75:_*G8]_.,
MBK9+R1K5(RG)7<4[N/JNWGZ^ILT445TGS(4444 %%%% !1110 4444 %%%%
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M#R:CK+23W-PQCL]/M\&6Y<#G&>BC(RQX&1U) /DW_"_?C1)8_P#"0Q_!UO\
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MF7>%)4#(*HX.>-AQR:^@D_9L^&"*%_X0G22 ,<PY/\Z7_AF[X8#_ )DC2/\
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MQCXY^"&F:CN>VU.\,%SM.TLDDEL'P1TX)KZSMK>*SMXH((UAAB4(D:#"JH&
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MQ797^KZ-X:MXEM+#3[99F+F)9%9E9E&!)*6SG/RH*]7_ .&XO!V/^17\8?\
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MA'MW3 *M&UN<G^+<".,$[*NXRBE)WZ?\ YU@:\J,Z_)[D7:3[/1:_>=/X/\
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MOINGP9$5K:QB.-,DL<*.!DDGZFJ_B7PEHGC*Q2RUW2;/6+1)!*L%] LJ*X!
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M)--]KG/]1K3P[Q3A[B?+?3?TWZKR.TTO2;+1+"&RTZS@L+.%=L=O;1+'&@]
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+2ML3*<IOFD[L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>adap-20230512.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 11:27:37 PM-->
<!--Modified on: 5/11/2023 11:27:37 PM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2022" targetNamespace="http://www.adaptimmune.com/20230512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:adap="http://www.adaptimmune.com/20230512" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20230512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20230512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="adap_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>adap-20230512_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 11:27:37 PM-->
<!--Modified on: 5/11/2023 11:27:37 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="adap-20230512.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="adap_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adap_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>adap-20230512_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 11:27:37 PM-->
<!--Modified on: 5/11/2023 11:27:37 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adap-20230512.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adap-20230512.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638194444579523588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638194444579523588" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638194444579523588" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638194444579523588" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638194444579523588" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638194444579523588" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638194444579523588" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638194444579523588" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638194444579523588" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638194444579523588" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638194444579523588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry_638194444579523588" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638194444579533599" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638194444579533599" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638194444579533599" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638194444579533599" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638194444579533599" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638194444579533599" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638194444579533599" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638194444579533599" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638194444579533599" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638194444579533599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638194444579533599" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638194444579543594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638194444579543594" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638194444579543594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638194444579543594" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140544669697136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adap_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adap_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adap_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>adap-20230512x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20230512.xsd" xlink:type="simple"/>
    <context id="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_BHNC9rZbGkCG4ie0X24FTQ_2_1">0001621227</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_XVVBD70Tn0GGcP8ZjSTI3A_3_1">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Hidden_BaeV3aqDwUOBC-fJo8d2Jw">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_8bZbWT-DIEyDS7X0YLDGug">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_nO0Pu-7nbESSRa8gTJSl7w">2023-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_KC_A0m0xrkiU-PHQfKR_gA">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_-ssh2WX-EUGd9W1GK2Ayfg_1_0">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_WuG8UCvZVk6dG2cs1TeI5g_1_2">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_igg612w8WE2Yl8TKo3Pn7A">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_tAFaxb8yXEi676wIukVY0A">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_Pvs_6DcuykyJuaSPoTvpqA">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_QJ_9qt237kWRPA9u3vcQiA">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_aA7EA3psL0SXmUuNaqX2pg">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_Ibl_bXNPLku-JIH7lyLfTQ">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_4AvE-d2AREqCtRtgOROALA">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_nWPOTxVl9US8UK15J13Xgg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_bSBIpg7iaUa0VgED5cByqg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_YBcU_uS3IEGReLwxdv9qAA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_pEHNQnSX00KpdSbXKwHa_g">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_0z11C1qmCEOIfbqE7ljezQ_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_kj5UasHEsk6YPlIxhTGWJQ_1_2">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Tc_YiQYCxVxh0KEyVpB8-QZXA_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q"
      id="Narr_WXxOJE5WLEuDKtl8z00KMA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ B3RL5APX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( (D\K%8D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ B3RL5F8*94CN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MB3RL5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " ")/*Q6%_HF]9($  "4$0  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MB3RL5I^@&_"Q @  X@P   T              ( !U0P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " ")/*Q6EXJ[',     3 @  "P              @ &Q
M#P  7W)E;',O+G)E;'-02P$"% ,4    " ")/*Q6'#AEZC\!   \ @  #P
M            @ &:$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ B3RL
M5B0>FZ*M    ^ $  !H              ( !!A(  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ B3RL5F60>9(9 0  SP,  !,
M         ( !ZQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  -10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adap-20230512x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="adap-20230512x8k.htm">adap-20230512x8k.htm</File>
    <File>adap-20230512.xsd</File>
    <File>adap-20230512_lab.xml</File>
    <File>adap-20230512_pre.xml</File>
    <File>adap-20230512xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adap-20230512x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "adap-20230512x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20230512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20230512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adap-20230512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "adap",
   "nsuri": "http://www.adaptimmune.com/20230512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adap-20230512x8k.htm",
      "contextRef": "Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adap-20230512x8k.htm",
      "contextRef": "Duration_5_12_2023_To_5_12_2023_jWMPbOr8CUqCfVeJ4RmQ-Q",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "adap_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.adaptimmune.com/20230512",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-23-009504-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-009504-xbrl.zip
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MBEWA"F7;!M#KLX1$1! Z?D0"<X),F8TBAZ&SA]+$;2H<Q:VFT$-9>[4$[=D
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M6HKJ]O^!RKD E=->5/G64E1W5T0UEIN?V9QN21FHG\J682HQED)RKPAI1KF
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M!3&LPT^"]7[X33>QY\WV^#POJOJ03/B)$ [;@^*_=[#R@22ZI9M'7R54^ZF
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M1^0 ?#[N4629I0F,AP/JG%P'00K#?V1P1#  #%\^:%3L,1SH*H7_(W/&-/!
MM#I@(-"(.J#X%S1MKDP @XJ1_Y'K- E]E@*DE?:$*XA9?APQ8]^XVRJ,>.P$
ME;[:/8P0*N<S,%GF)'!J(S A!/)Q96T*<R)\8*XI/"Q;F)(>@&S[W?:1C,OE
M>+I8#;N]^<0Q=[U@).\R@59D[@J9Y0$*9/YOE-TMM?LM<7KA[!%Z !#/UR\4
M$%3.;%_:'4$/-^]*]' KQ!:2J_.-? :; .R8VQS=_TEA4]=DH[G6$X-24#X%
MB"%WG!!N/FU!!Y>*$+XNE*PP!RU1 ,TH@)S]^&<:)E<9\Q%_GE_"Y$@,H+3
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M@F.OH4)#A<],A2JTR.,X8Y[_*:-L@C9M19LK*'/*)J"_^=Y?G#JSW(*,"N2
M/&[$]:<"M<0LX>M &L($<_(CG4RO0*:!\2^#F.BLBH%6P;;C+Q=?22-0]9G/
MPU#K:.DHN@%1_[6Z.ZE"1=.S<?Q,EZ/H03F*9I%@$2H[>87%\,7GXHO/D&%+
M$'N1_15&SOW,1]W?\G3?+.4%F+0PI47^2I;FZ15S9L+@+D36*P%0SB6)7Y8:
M8VCSL+3)<?@AC$ O0"P8AB*:[O-L1A;$:<14SA:Z>[B14-! %.K.X"S_7I8
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M75Y+AOP!"!\&1 ZD(?OZ1@P3<>;:W.6M5\5=,<_0[^[56[Q[-):7C]Z%<K%
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MOXG8HTA^FG>F7&4B#= [G&!CN!QE+?4A+4 +L(VO&RF#L\X[!D.R7/:(?"D
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M5HE&J^&XRMLEXK;S/S._E@(0F+4  +"!FZ]VY0O-^DIQK#^P>!1#P*=E6TL
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M42=ZG&^"J05T#D"/K6;?&MC=!0Z;BX3"[N%?U[M?ML6OW@0D[V_L@7P))S2
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M,#(S,#4Q,BYX<V102P$"% ,4    " ")/*Q6(JN)G)0%  "U/@  %0
M        @ 'Z P  861A<"TR,#(S,#4Q,E]L86(N>&UL4$L! A0#%     @
MB3RL5E&"1320!   8"H  !4              ( !P0D  &%D87 M,C R,S U
M,3)?<')E+GAM;%!+ 0(4 Q0    ( (D\K%8G@8?S@Q,  -&*   4
M      "  80.  !A9&%P+3(P,C,P-3$R>#AK+FAT;5!+ 0(4 Q0    ( (D\
MK%:+V'&0QT4  ,%I!  8              "  3DB  !A9&%P+3(P,C,P-3$R
A>&5X.3ED,2YH=&U02P4&      4 !0!- 0  -F@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
